Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tanibirumab in recurrent glioblastoma
NCT03033524Phase 2Completed
- Sponsor
- PharmAbcine
- Start
- Feb 2016
- Primary completion
- Jun 2017
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of olinvacimab in glioblastoma (GBM), sponsored by PharmAbcine. Started Feb 2016; status: completed.
02
Drugs
olinvacimab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03033524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03033524.